Want to see AU:VIT full AI Analyst Report?
Cronos Australia Ltd. (VIT) AI Stock Analysis
Cronos Australia Ltd.
(ASX:VIT)
The overall score of 39 is driven primarily by severe fundamental weaknesses, led by a collapse in profitability, negative cash flow, and an unprofitable valuation profile. The score is further suppressed by continuous bearish momentum across all major technical moving averages.
Cronos Australia Ltd. (VIT) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 13.25M
- Dividend Yield
- ―
- Average Volume (3M)
- 454.99K
- Price to Earnings (P/E)
- -3.0
- Beta (1Y)
- 1.73
- Revenue Growth
- 5.74%
- EPS Growth
- -222.22%
- Country
- Australia
- Employees
- 72
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Cronos Australia Ltd. Business Overview & Revenue Model
Company Description
Established in 2018 and based in South Yarra, Australia, Vitura Health Limited focuses on the supply and marketing of medicinal cannabis goods throughout Australia and the Asian market. The company manages a portfolio of key brands, such as CanView,...
Cronos Australia Ltd. Financial Statement Overview
Summary
Despite slight revenue growth, profitability has severely deteriorated, culminating in a net loss and negative cash flows in 2026. While the balance sheet retains a manageable debt-to-equity ratio, shrinking equity and increasing debt highlight growing fundamental risks.
Income Statement
25NegativeBalance Sheet
55NeutralCash Flow
25Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 131.16M | 131.16M | 124.04M | 123.87M | 117.34M | 66.99M |
| Gross Profit | 3.92M | 3.92M | 33.75M | 34.22M | 25.96M | 25.43M |
| EBITDA | 1.20M | 1.20M | 7.52M | 7.08M | 21.08M | 10.87M |
| Net Income | -4.39M | -4.39M | 3.32M | 3.51M | 13.81M | 6.05M |
Balance Sheet | ||||||
| Total Assets | 76.74M | 76.74M | 75.49M | 71.28M | 46.90M | 42.87M |
| Cash, Cash Equivalents and Short-Term Investments | 5.35M | 5.35M | 7.58M | 11.35M | 18.85M | 16.08M |
| Total Debt | 16.40M | 16.40M | 11.97M | 11.02M | 1.71M | 5.06M |
| Total Liabilities | 33.80M | 33.80M | 27.89M | 32.84M | 11.99M | 16.79M |
| Stockholders Equity | 43.55M | 43.55M | 48.20M | 38.78M | 34.98M | 26.10M |
Cash Flow | ||||||
| Free Cash Flow | -216.80K | -216.80K | 2.58M | 6.21M | 8.78M | 13.13M |
| Operating Cash Flow | -91.03K | -91.02K | 2.67M | 7.00M | 9.71M | 13.50M |
| Investing Cash Flow | -3.74M | -3.74M | -13.87M | -13.20M | -837.72K | 2.00M |
| Financing Cash Flow | 1.60M | 1.60M | 7.43M | -1.30M | -6.10M | -1.50M |
Cronos Australia Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VIT, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 44.78 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:VIT.
Cronos Australia Ltd. Peers Comparison
Overall Rating
AU:VLS82Outperform
AU:CAN53Neutral
AU:LGP45Neutral
AU:EXL43.2Neutral- AU:VIT39Underperform
AU:PKP39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:VLS | 82Outperform | AUD 147.70M | 13.70 | 19.91% | 5.29% | 12.19% | 22.36% |
| AU:CAN | 53Neutral | AUD 8.30M | 0.30 | 64.70% | ― | -24.22% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:LGP | 45Neutral | AUD 49.68M | -13.04 | -1.67% | ― | 15.21% | -141.82% |
| AU:EXL | 43Neutral | AUD 2.72M | -0.59 | -50.35% | ― | -4.87% | -9.78% |
| AU:VIT | 39Underperform | AUD 13.25M | -2.98 | -9.80% | ― | 5.74% | -222.22% |
| AU:PKP | 39Underperform | AUD 21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:VIT | Cronos Australia Ltd. | 0.02 | -0.04 | -67.74% | |
| AU:EXL | Elixinol Wellness Ltd | 0.01 | 0.00 | 25.00% | |
| AU:CAN | Cann Group Ltd. | 0.01 | -0.00 | -9.09% | |
| AU:VLS | Vita Life Sciences Limited | 2.74 | 0.47 | 20.76% | |
| AU:LGP | Little Green Pharma Ltd. | 0.06 | -0.07 | -53.85% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.02 | -0.01 | -23.81% |
Cronos Australia Ltd. Corporate Events
Vitura Health Reshapes Board to Bolster Medical and Tech Expertise
Vitura Health Limited has launched a search for a new director with deep medical and technology expertise as part of a broader board renewal and succession planning effort. The board believes this appointment will support execution of its Three Horiz...
Vitura Health Sets 2026 AGM as It Expands Digital Health and Therapeutics Footprint
Vitura Health Limited has released the documents for its 2026 Annual General Meeting, which will be held virtually on 27 November 2026, including the formal notice, proxy form, and related access materials. The meeting comes as Vitura continues to le...
Vitura Health posts strong Q1 and sharp EBITDA rebound as Three Horizon Plan targets profitability
Vitura Health has reported an encouraging start to FY2027, with first-quarter revenue up 4.8 per cent year-on-year, EBITDA almost tripling and operating expenditure declining by 9.5 per cent. Management has launched a Board-endorsed Three Horizon Pla...
Vitura Health installs permanent CFO as digital health and cannabis portfolio expands
Vitura Health Limited has appointed James Frayne as its Chief Financial Officer, with his tenure commencing on 29 September 2026, marking the end of Tom Howitt’s period as interim CFO. The board publicly acknowledged Howitt’s contribution...
Vitura Health Sets 2026 AGM as Digital Health Portfolio Expands
Vitura Health Limited has scheduled its 2026 Annual General Meeting for 27 November in Melbourne, with director nomination closing on 27 September in line with ASX requirements. Further meeting details will be circulated to shareholders and the marke...
Vitura hit by BUPA telehealth shift but reiterates FY2027 growth outlook
Vitura Health has disclosed a material setback for its Doctors on Demand telehealth unit after BUPA Australia decided to redirect all international members, including overseas visitors and students, from Doctors on Demand to rival platform Hola Healt...
Vitura Health pivots to disciplined growth after profit slump in FY2026
Vitura reported FY2026 operating revenue of $131.2 million, up 5.7% year-on-year, driven by higher unit volumes, strong growth in clinics and services, and more than doubled nicotine vaping product revenue. However, normalised EBITDA fell to $3.0 mil...
Vitura Health Files 2026 Corporate Governance Statement with ASX
Vitura Health Limited has lodged its annual corporate governance statement for the financial year ended 30 June 2026, confirming that the document is current as of 25 August 2026 and approved by the board. The statement is contained within its financ...
Vitura Health Slips to Loss as Cannabis Price Compression Squeezes Margins
Vitura Health reported a consolidated loss after tax of about $4.4 million for the year to 30 June 2026, reversing a prior-year profit despite a 5.7% rise in revenue to $131.2 million driven by growth in product distribution and medical consultation...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026